Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)

Overview

AC-ICAM (Sidra-LUMC Atlas and Compass of Immune-Cancer-Microbiome interactions) is a multi-omics resource of 348 treatment-naive primary colon cancers profiled with RNA-seq, WES, TCR-seq, 16S rRNA-seq, and tumor WGS on paired tumor/normal colon tissue PMID:37202560.

Composition

  • 348 treatment-naive patients with primary colon adenocarcinoma; fresh-frozen tumor and matched healthy colon tissue; median follow-up 4.6 years PMID:37202560.
  • Additional ICAM42 subset (n=42) profiled with 16S rRNA sequencing PMID:37202560.

Assays / panels (linked)

Papers using this cohort

  • PMID:37202560 — Roelands et al., integrated tumor, immune and microbiome atlas of colon cancer. TCGA-COAD was used as a comparator due to limited survival follow-up and tumor-purity selection constraints PMID:37202560.

Notable findings derived from this cohort

  • Consensus clustering on the 20-gene ICR signature segregated AC-ICAM into ICR-high/medium/low subtypes; ICR-high vs ICR-low HR 0.54 (95% CI 0.34–0.86, P=0.0095) PMID:37202560.
  • ICR outperformed CMS and MSI classifications for prognosis and retained prognostic value within CMS4/mesenchymal tumors PMID:37202560.
  • Quantifying genetic immunoediting further refined ICR’s prognostic value, and a Ruminococcus bromii-driven microbiome signature combined with ICR (mICRoScore) identified a subgroup with excellent survival PMID:37202560.

Sources

This page was processed by crosslinker on 2026-04-08.